Gene · 126328
NDUFA11: NADH:ubiquinone oxidoreductase subunit A11
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. NDUFA11: NADH:ubiquinone oxidoreductase subunit A11. Genes, record 126328. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/126328
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q86Y39 | NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 11 | 141 | 7 | Ensembl, GeneID, HGNC |
Source UniProt
Patents25
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 54918 | Q86Y39 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 4777 | Q86Y39 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2802 | Q86Y39 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2802 | Q86Y39 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 4777 | Q86Y39 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 55013 | Q86Y39 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 157984 | Q86Y39 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 235353 | Q86Y39 | Espacenet |
| JP 2017121241 A | 2017-07-13 | 235353 | Q86Y39 | Espacenet |
| JP 2015516143 A | 2015-06-08 | 235353 | Q86Y39 | Espacenet |
1 to 10 of 25
See all 25 patentsDrugs4
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ME-344 | CHEMBL5314386 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | ChEMBL |
| METFORMIN | CHEMBL1431 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | ChEMBL |
| METFORMIN HYDROCHLORIDE | CHEMBL1703 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | ChEMBL |
| NV-128 | CHEMBL3545135 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | ChEMBL |
Trials1,218
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07604870 | METFORMIN | PHASE2 | ClinicalTrials.gov | |
| NCT07604779 | METFORMIN | ClinicalTrials.gov | ||
| NCT07603505 | METFORMIN | PHASE1 | ClinicalTrials.gov | |
| NCT07589387 | METFORMIN | ClinicalTrials.gov | ||
| NCT07588932 | METFORMIN | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT07585396 | METFORMIN | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07582471 | METFORMIN | ClinicalTrials.gov | ||
| NCT07520110 | METFORMIN | PHASE3 | ClinicalTrials.gov | |
| NCT07516821 | METFORMIN | ClinicalTrials.gov | ||
| NCT07513480 | METFORMIN | ClinicalTrials.gov |
1 to 10 of 1,218
See all 1,218 trialsNIH grants359
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | NDUFA11 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
| P2CHD050924 | Carolina Population Center | 2 | 2025 |
| P30CA093373 | Cancer Center Support Grant P30 | 2 | 2025 |
| P30DK043351 | Center for the Study of Inflammatory Bowel Disease at Massachusetts General Hospital | 2 | 2025 |
| P30DK063491 | Diabetes Research Center (DRC) | 2 | 2025 |
| P30ES007048 | Environmental Exposures, Host Factors and Human Disease | 2 | 2025 |
| P40OD018537 | Bloomington Drosophila Stock Center at Indiana University | 2 | 2025 |
| P01AG019724 | Frontotemporal Dementia: Genes, Images, and Emotions | 1 | 2025 |
| P01CA066996 | Development of Novel Therapeutic Strategies in Human Leukemias | 1 | 2025 |
| P01CA229086 | The impact of changes in chromatin architecture on cancer phenotypes and tumor progression | 1 | 2025 |
1 to 10 of 359Source NIH's project files
See all 359 nih grantsPapers357
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Prognostic characteristics of disulfidptosis-related genes across cancers and their potential implications in osteosarcoma. | Sci Prog | 2026 | 42370567 | PubTator, text mining | PubMed |
| Disulfidptosis-related genes define a prognostic signature and novel therapeutic targets in Ewing's sarcoma through transcriptomic analysis and experimental validation. | Front Immunol | 2026 | 42064080 | PubTator, text mining | PubMed |
| Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. | Curr Issues Mol Biol | 2026 | 41899406 | PubTator, text mining | PubMed |
| A genus-wide interaction atlas across NS4B orthologues identifies a conserved role for UFMylation in orthoflavivirus replication. | Nat Commun | 2026 | 41826287 | PubTator, text mining | PubMed |
| Mitochondrial abnormalities in idiopathic inflammatory myopathies. | Clin Exp Rheumatol | 2026 | 41738252 | PubTator, text mining | PubMed |
| Machine learning identifies disulfidptosis-related gene signature for pancreatic cancer prognosis and immune infiltration. | Discov Oncol | 2026 | 41591656 | PubTator, text mining | PubMed |
| Integrated proteomics and metabolomics reveal phytosesquiterpene lactones inhibit TNBC cell activity by depleting ATP synthesis and reprogramming primary metabolism. | Sci Rep | 2026 | 41530404 | PubTator, text mining | PubMed |
| Prediction of the Prognosis and Treatment Responses Based on the Characteristics of Disulfidptosis-Related Genes in Patients with Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma | Endocr Metab Immune Disord Drug Targets | 2026 | 39945255 | PubTator, text mining | PubMed |
| Mitochondrial energy metabolism genes as prognostic biomarkers in clear cell renal cell carcinoma via single-cell and bulk RNA sequencing analyses. | Discov Oncol | 2025 | 41364140 | PubTator, text mining | PubMed |
| Molecular subtypes and prognostic signature rooted in disulfidptosis highlight tumor microenvironment in lung adenocarcinoma. | Chin J Cancer Res | 2025 | 41246257 | PubTator, text mining | PubMed |
1 to 10 of 357
See all 357 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/126328
GET https://conductscience.org/api/genes/v1/126328/patents?page=2